No abstract

Background: More than 50% of advanced NSCLC patients are older than 65 years old (y), with a median age at diagnosis of 68 y. This group of patients have been usually underrepresented in clinical trials. The aim of our study is to compare whether clinical characteristics, toxicity, response rate, overall survival (OS), and progression free survival (PFS) are different in p > 70y vs. < 70y, treated with platinum based chemotherapy. Method: We reviewed the database of the Instituto Oncologico Córdoba, Argentina (IONC). Survival curves were made up by Kaplan-Maier method and compared using the log-rank test. Results: Out of 198 p; 103 p (52 %) < 70y, and 95 p (48 %) > 70y We found significant differences in OS (9.4 vs. 7.5 months, p¼0.003) and PFS (6.4 vs. 5.1 months, p¼0.002) Significant differences in OS were also found between the two groups regarding anemia, Performance status (PS) and response rate with no difference on sex and histology. Conclusion: Significant differences in OS and PFS were evident between both groups. We observed increased toxicity in p > 70y, but without greater treatment-related mortality. OS and PFS were superior in patients treated with platinum-based doublets when compared to monotherapy (according to historical records); therefore we should choose the former in elderly patients.

No abstract

No abstract

Germany. Methods: This retrospective analysis of nationwide hospital discharge data in Germany between 2013 and 2016 comprises 121837 patients of whom 36051 (29.5%) underwent surgical anatomic resection. Hospital volumes were defined according to the number of patient resections for lung cancer in each hospital, and patients were categorized into 5 quintiles based on hospital caseload volume. A logistic regression model accounting for death according to sex, age, comorbidity, and resection volume was calculated, and effect modification was evaluated using the ManteleHaenszel method. Results: In-house mortality ranged from 2.1% in very highvolume centers to 4.0% in very low-volume hospitals (p<0.01). In multivariable logistic regression analysis, lower in-house mortality in very high-volume centers performing > 140 anatomic lung resections per year was compared with very low-volume centers performing < 27 resections (OR, 0.58; CI, 0.46 to 0.72; p<0.01). This relationship also held for failure to rescue rates (12.9 vs 16.7%, p¼0.01), although a greater number of extended resections were performed (23.1 vs. 14.8%, p<0.01). Conclusion: Hospitals with high volumes of lung cancer resections performed surgery with a higher ratio of complex procedures and achieved reduced in-house mortality, fewer complications, and lower failure to rescue rate.